TPTX
Income statement / Annual
Last year (2021), Turning Point Therapeutics, Inc.'s total revenue was $30.83 M,
an increase of 23.32% from the previous year.
In 2021, Turning Point Therapeutics, Inc.'s net income was -$236.55 M.
See Turning Point Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
| Period Ended |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
| Operating Revenue |
$30.83 M |
$25.00 M |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$25.00 M
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$30.83 M
|
$25.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
1
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$192.98 M
|
$113.41 M
|
$57.94 M
|
$21.06 M
|
$15.24 M
|
| General & Administrative Expenses |
$75.85 M
|
$73.43 M
|
$19.78 M
|
$4.58 M
|
$1.49 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$75.85 M
|
$73.43 M
|
$19.78 M
|
$4.58 M
|
$1.49 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$268.83 M
|
$186.84 M
|
$77.72 M
|
$25.64 M
|
$16.73 M
|
| Cost And Expenses |
$268.83 M
|
$186.84 M
|
$77.72 M
|
$25.64 M
|
$16.73 M
|
| Interest Income |
$0.00
|
$0.00
|
$0.00
|
$856.00 K
|
$136.00 K
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$3.97 M
|
$2.39 M
|
$1.58 M
|
$138.00 K
|
$63.00 K
|
| EBITDA |
-$232.58 M |
-$154.90 M |
-$70.55 M |
-$24.65 M |
-$16.53 M |
| EBITDA Ratio |
-7.54
|
-6.2
|
0
|
0
|
0
|
| Operating Income Ratio |
-7.67
|
-6.47
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$1.45 M
|
$4.54 M
|
$5.59 M
|
$856.00 K
|
$136.00 K
|
| Income Before Tax |
-$236.55 M
|
-$157.29 M
|
-$72.13 M
|
-$24.78 M
|
-$16.59 M
|
| Income Before Tax Ratio |
-7.67
|
-6.29
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$1.00 K
|
$1.00 K
|
| Net Income |
-$236.55 M
|
-$157.29 M
|
-$72.13 M
|
-$24.79 M
|
-$16.59 M
|
| Net Income Ratio |
-7.67
|
-6.29
|
0
|
0
|
0
|
| EPS |
-5.79 |
-3.85 |
-2.99 |
-1.66 |
-1.11 |
| EPS Diluted |
-5.79 |
-3.85 |
-2.99 |
-1.66 |
-1.11 |
| Weighted Average Shares Out |
$40.84 M
|
$40.84 M
|
$24.12 M
|
$14.94 M
|
$14.94 M
|
| Weighted Average Shares Out Diluted |
$40.84 M
|
$40.84 M
|
$24.12 M
|
$14.94 M
|
$14.94 M
|
| Link |
|
|
|
|
|
